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Abstract 
Nasopharyngeal carriage studies provide insights into the local prevalence of circulating 
pneumococcal serotypes. These data are critical for vaccination monitoring purposes, as they 
allow predicting and assessing their impact. Scarce data are available on the carriage of 
pneumococcal serotypes in Morocco. Here, we describe the prevalence of Streptococcus 
pneumonia carriage and serotype distribution among195 healthy infants and young children 
recruited at a vaccination clinic and 697 pediatric patients aged from 2 to 59 months admitted 
to a Moroccan reference hospital with severe pneumonia. Carriage rates were 40.5% (79/195) 
for healthy children and 22.8% (159/697) among sick ones. Most frequent circulating 
serotypes included 6A, 6B and 19F all included in the current 13-valent anti-pneumococcal 
conjugate vaccine recently introduced in the country. Monitoring of circulating serotypes 
remains necessary after vaccine introduction to assess whether serotype replacement is 
occurring.  
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Background 
Pneumococcal disease is the leading cause of vaccine preventable deaths and Streptococcus 
pneumoniae is estimated to be responsible for 11% of all deaths in children less than five 
years of age worldwide, mostly due to community-acquired pneumonia[1].Nasopharyngeal 
colonization is known to play an important role in the development and transmission of 
pneumococcal disease. Infants and young children are considered to be the main reservoir of 
this pathogen[2].Studies show that it is essential to monitor prospectively the pneumococcal 
circulating serotypes to predict and assess the impact of the vaccine introduction in a given 
community and also to allow the demonstration of whether serotype replacement may be 
occurring[3]. 
In Morocco, a middle-income country in Northern Africa, pediatric pneumonia remains a 
major public health challenge. A recent study conducted in 2010 in a tertiary hospital among 
admitted children under five years of age with clinically severe pneumonia, reported that the 
etiologies of pneumonia were mostly viral, and that bacterial pathogens were rarely isolated, 
affecting only 3.5% of the patients[4]. The Moroccan Ministry of Health introduced in 2010 
the pneumococcal (13-valent) conjugate vaccines into its expanded program of immunization 
(EPI) schemes among other control measures[5]. Due to the scarce available data in 
Morocco[6], we aimed to investigate pneumococcal carriage and serotype distribution among 
healthy infants recruited at vaccination clinics and sick children admitted with a diagnosis of 
severe pneumonia at a referral tertiary hospital in Morocco.  
 
Material and methods 
Study area and population  
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The study was conducted at the Hôpital d’Enfants de Rabat (HER)- the only public hospital 
dedicated to children in the region- and at four heath centers located in the area of Rabat-Salé-
Zemmour-Zair (RSZZ Rabat province). The proportion of children under five in the region of 
RSZZ has been estimated at 5.66%[5]. 
Study design 
The study population was recruited from HER among patients admitted for severe clinical 
pneumonia according to WHO definition[7]during a one-year survey from November 2010 to 
December 2011, as part of a wider research protocol trying to define the epidemiology and 
etiology of respiratory distress at HER[4]. Healthy children who were visiting primary health 
care centers of the province of Rabat for routine vaccination were also recruited from 
February to March 2011. These sites were selected randomly from the list of the primary 
health care of the region RSZZ. The sample size for the community study (n=200) was 
calculated based on the preliminary carriage rates found at HER in children with WHO-
defined severe clinical pneumonia[4]. 
Data collection  
Children were recruited both at the wards of HER or at the health centres only after an 
informed consent was signed by parents or legal guardians. The study team would then 
administer standardized questionnaires and obtain nasopharyngeal samples from the children 
using a mini culturette extra-thin flexible wire swab with its tip, in addition to other 
procedures explained elsewhere[4]. 
Laboratory methods 
The nasopharyngeal cultures were injected into Stuart transport medium tubes. Samples were 
processed on a daily basis: homogenized, aliquoted, and frozen at -70ºC. Nasal samples were 
cultured using conventional methods and bacterial isolates were identified by colony 
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morphology and biochemical tests. Molecular capsular typing of pneumococcal strains 
isolated by conventional culture was investigated using sequential multiplex Real Time PCR 
targeting 24 common serotypes (1, 3, 4, 5, 6A,6B, 7F/A, 8, 9V/A/N/l, 14, 15B/C, 18C/B, 
19A, 19F/B/C, 23A and 23F)[8].  
Data analysis 
Study variables were counted and summarized in frequency tables. Quantitative variables are 
summarized as Means with their corresponding standard deviations. Qualitative variables are 
presented as a percentage with 95% confidence interval. As the inclusion of patients from the 
peripheral health posts was only conducted to provide a baseline assessment of carriage rates 
among theoretically healthy children, but was not designed to infer differences or 
associations, no formal statistical comparisons are presented between both groups.  
 
Results  
Seven hundred patients were admitted for severe clinical pneumonia during the one- year 
survey and were eligible for the study, and 200 healthy children were recruited from primary 
health care centers during one month. The proportion of infants less than 1 year of age, was 
30.6% (214/700) among the admitted patients and 70.7% (138/195) in children from the 
community. Three samples from the hospitalized group and five from the outpatient group 
were not suitable for analyses. Thus, nasopharyngeal carriage of streptococcus pneumonia 
among admitted patients was 22.8% (159/697), and 40.5% (79/195) among children attending 
the primary care centers. 
Among admitted patients, monthly distribution of carriage was significantly different (data 
not shown, p<0.001), and carriage was significantly more frequent during spring and summer 
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(~31-32%) than during autumn or winter (~19-20%) (p=0.003). Seasonality could not be 
assessed among outpatients as recruitment lasted only one month.  
Carriage rates also varied, albeit no significantly, according to number of doses received of 
pneumococcal vaccine. Thus, in infants, carriage rates were 21.2%, 24.5%, 31.3% and 33% 
among those not having received any dose, 1, 2 or three doses respectively. 24.0% and 31.6% 
of the children aged over one year and not having received any dose or one dose, respectively, 
were carriers, while none of those having received at least two doses were positive. 
Serotype distribution was assessed by molecular methods in 74.2% (118/ 159) and 58.2% 
(46/79) of the individuals having test positive for pneumococcus. The most frequent 
circulating serotypes included 6A, 6B and 19F/B/C. Their proportion among healthy children 
was 2to 8 times higher in children less than 12 months of age; while19F/B/C was twofold 
higher among children having received at least one dose of the 13-valent pneumococcal 
conjugate vaccine. In this population serotype, 6A was similarly frequent, but 6B was only 
isolated among incompletely (one or two doses) vaccinated children. Vaccine coverage for the 
circulating serotypes among children for which individual serotype data were available was 
55.9% (66/118) among hospitalized children and 52.1% (24/46) for healthy children. Certain 
serotypes for which inter-group differentiation was not possible because of the diagnostic 
method utilized (i.e. 19 F/B/C) were also observed. Table 1 shows the characteristics of the 
children included in this study and the distribution of serotypes according to the status group.  
 
Discussion 
This study showed a moderately low nasal carriage of pneumococci, ranging from 23% to 
40% in two very distinct pediatric populations, namely sick children with clinical severe 
pneumonia and healthy children. This analysis gives baseline information of the current status 
of pneumococcal carriage among children in Morocco, although it is worth noting that the two 
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groups studied do differ significantly in some important variables, such socioeconomic status 
or exposure to antibiotics or smoking. These differences probably reflect different patterns of 
health seeking behavior at the health post and hospital level. 
The predominant serotypes identified in these population were 6A, 19F/B/C, 6B, 23A and 
23F serotypes. This result could be explained by the fact that the samples were obtained 
shortly after the introduction of the vaccine in the EPI schedule. Similar results were found in 
the Region of Marrakech among healthy children[9]  and admitted patients in Casablanca[10]. 
At least half of the individual serotypes identified are included in the current vaccine used by 
the national immunization program introduced in November 2010[11]. Actual coverage of 
circulating serotype of this vaccine in Morocco may be even higher, as some of the grouped 
serotypes identified are also included in the vaccine. Consequently, the wider implementation 
of this vaccine, for which coverage rates were still low among admitted patients with severe 
pneumonia at the time of the study, may not only contribute to the observed decreased 
pneumococcal associated severe disease, but also asymptomatic carriage[12]. The potential 
public health impact of this vaccine, once it has been adequately deployed throughout the 
country, seems therefore significant. In low and middle-income countries, and under natural 
conditions of exposure, children become quickly colonized by pneumococci, and it is not 
uncommon to find moderate to high carriage rates (often exceeding 2/3 of the children) in 
countries that have not yet implemented vaccinations program, particularly among young 
infants[13]. In our study, we found lower than expected carriages rates of those serotypes 
most commonly described in the literature[13]. Continuous monitoring and repeated 
investigations for the serotype distribution of pneumococcal carriage and invasive disease 
remains necessary in Morocco, to adequately detect the emergence of new circulating 
serotypes[14] and prevent further morbidity and mortality as well as assess the impact of the 
recently implemented vaccine.  
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Table 1: Baseline characteristics and microbiological finding among admitted children with 
clinical severe pneumonia and healthy patients. 
Patient's variables   Hospitalized 
patients 
N=700 
Healthy 
Community 
Controls 
N=200 
n/N (%) n/N (%) 
Basic 
demographics 
Female gender  251/700 (35.9) 99/195 (50.8) 
Age in months: Mean (SD) 21.5 (14.5) 8.9 (11.1) 
Infants (<1 year) 214/700 (30.6) 138/195 (70.8) 
Both parents unemployed 120/691 (17.4) 9/195 (4.6) 
Both parents employed 58/691 (8.4) 48/195 (24.6) 
Medical insurance 181/696 (26.0) 92/193 (47.2) 
Proportion of children living in 
house>6 people 
268/700 (38.3) 49/195 (25.1) 
Number of rooms in house: 
Mean (SD) 
2.2 (1.1) 1.8 (0.9) 
Breastfeeding >6months 422/697 (60.5) 56/195(28.7) 
Prior admission due to 
respiratory condition 
227/700 (32.4) 18/194 (9.3) 
Smokers at home 282/699 (40.3) 58/195 (29.7) 
Pre-recruitment use of 
antibiotics 
206/700 (29.4) 34/195 (17.4) 
At least one dose of 
Pneumococcal vaccine 
117/700 (16.7) 137/195 (70.3) 
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Bacterial carriage 
in the nasopharynx 
Positive pneumococcus in NPA 159/697 (22.8) 79/195 (40.5) 
Streptococcus 
pneumoniae 
serotypes 
distribution 
Non-typable pneumococci 41/159(25.8) 33/79(41.8) 
Typable pneumococci 118/ 159(74.2) 46/79 (58.2) 
18 C/B 5/118 (4.2) 1/79 (1.3) 
19 F/B/C 22/118(18.6) 11/79 (13.9) 
23 A* 6/118(5.1) 5/79(6.3) 
23 F 11/118(9.3) 3/79(3.8) 
4 - 1/79(1.3) 
6A 34/118(28.8) 13/79(16.5) 
6B 21/118(17.8) 10/79(12.7) 
8* - 1/79 (1.3) 
9V/A/N/L 6/118(5.1) 1/79 (1.3) 
19A 10/118(8.5) - 
7 FA 2/118(1.7) - 
3 1/118(0.8) - 
*Serotypes not included in the 13-valent pneumococcal conjugate vaccines. 
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